Nov 22 (Reuters) - Mirati Therapeutics Inc is attracting fresh takeover interest from large pharmaceutical companies ahead of updates to its drug pipeline, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.

Shares closed 15.5% higher at $86.11 following the report, giving the company a market capitalization of about $4.3 billion.

Larger drugmakers have been considering taking over the company, the report said, although there are currently no formal bids.

Mirati has become a more attractive target for companies seeking to expand their cancer treatment offerings since larger rival Seagen Inc. opted to stay independent.

The cancer drug developer has been weighing strategic options including a potential sale for some time, the report added.

The U.S. Food and Drug Administration is due to decide on the company's lung cancer treatment adagrasib by Dec. 14, and an approval will make it a competitor to Amgen's Lumakras.

A spokesperson for Mirati declined to comment on the report. (Reporting by Leroy Leo in Bengaluru; Editing by Krishna Chandra Eluri and Sriraj Kalluvila)